The source of most stem cell infusions is now G-CSF mobilized peripheral blood rather than BM. respectively. By multivariable analyses, transplantation in 1stremission was the most important predictor of transplant success. Pretransplant evidence of minimal residual disease, especially as recognized by circulation cytometric analysis, was associated with both lesser overall survival and relapse-free survival. VU6005649 Compared to a similar cohort of individuals transplanted from 19901997, overall survival is similar for individuals transplanted in 1stremission, with lower non-relapse mortality becoming offset by higher rates of relapse in individuals transplanted VU6005649 VU6005649 more recently. == Intro == For adults with ALL, the indications for, and timing of, allogeneic hematopoietic cell transplantation (HCT) continue to be debated.[13] Over the past 2025 years, refinements in conditioning regimens, GVHD prophylaxis and treatment, donor selection and supportive care have been made in an effort to improve transplant results. The methodology used to define minimal residual disease (MRD) continues to evolve with sensitive flow cytometric methods and PCR monitoring of molecular markers redefining relapse.[4,5] Criteria for classifying chronic GVHD also have been revised and await validation.[6] Given these modifications over time, we performed a retrospective analysis of consecutive adult ALL individuals who underwent allogeneic HCT with full-intensity conditioning between 1998 and 2006. Multivariable analyses were performed, focusing on medical factors, as well as signals of MRD, for his or her association with transplant end result. These current results were then compared to a similar cohort of individuals transplanted between 1990 and 1997, the results of which were published previously.[7] == MATERIALS AND METHODS == == Patient and disease characteristics == Patients included in this analysis had a diagnosis of ALL, were 18 years of age, received a full-intensity conditioning regimen and underwent HCT between January 1, 1998 and December 31, 2006. Written educated consent was from all individuals and donors using forms authorized by the Institutional Review Table of the Fred Hutchinson Malignancy Research Center. Pretransplant patient characteristics are summarized inTable 1. Median age was 36.1 (range, 18.161.8) yrs. Individuals were classified as Serpinf1 having B- or T-cell ALL based on immunophenotyping. B cell maturity at analysis was characterized as immature or mature: Immature B cells indicated TdT and/or CD34 and/or CD10; mature B cells indicated CD20, CD22, or SIg and did not communicate any immature markers.[8] Myeloid markers were defined as the expression of CD13 or CD33. Cytogenetic studies were performed on bone marrow (BM) or peripheral blood cells. Karyotypes were grouped as normal, Philadelphia chromosome positive (Ph+), additional unfavorable abnormalities (7, +8, or 11q23 rearrangement) and miscellaneous abnormalities.[9] Patients were considered to be Ph+if conventional cytogenetics were positive for t(9;22) or fluorescencein situhybridization (FISH) studies were positive for the BCR/ABL rearrangement. There were too few PCR studies done pretransplant to be helpful. Remission was defined as <5% blasts by morphology in marrow specimens that were >20% cellular. == Table 1. == Patient and Donor Characteristics Number of individuals unless otherwise specified Of 4 wire blood transplants, 2 were single unit transplants and 2 were double unit transplants Ph+includes individuals having a t(9;22) only, t(9;22) in addition additional clonal abnormalities, or BCR/ABL positive by FISH analysis Includes 7, +8 or 11q23 rearrangement Additional clonal abnormalities Extramedullary disease occurring before or at the time of transplant MRD = minimal residual disease, N.D. = no data. Pretransplant studies = studies done proximate to conditioning regimen. Eleven of the 59 individuals had two irregular markers (circulation cytometry +irregular karyotype or irregular FISH) N = 158 (wire blood transplant donors excluded) == Donor selection and stem cell collection == Donor characteristics are outlined inTable 1. Median donor age, excluding.